Drug Discovery 2022: driving the next life science revolution

Dr Stuart Cockerill

Dr Stuart Cockerill
Dr Stuart Cockerill
CSO
Reviral/Pfizer
Delegate / Speaker

Presentations at Drug Discovery 2022: driving the next life science revolution

Profile of Dr Stuart Cockerill

Dr Stuart Cockerill. After a Ph.D.in Organic Chemistry at University of Leeds with Professor Philip Kocienski and a Post-doctoral Fellowship at Cornell University (NY, USA) with John McMurry; Stuart joined the Wellcome Foundation, where he worked on antivirals before moving into the oncology therapeutic area at GlaxoWellcome. He is a co-inventor of Tykerb, a breast cancer treatment now marketed by Novartis. After ten years at Arrow Therapeutics and Astra Zeneca in Respiratory Syncytial Virus and Hepatitis C Virus, Stuart was part of a team who founded ReViral Ltd in 2011 and led the identification of sisunatovir. Reviral Ltd was acquired by Pfizer in June 2022.

Email

Please login to send a Private Message

Hosted By

ELRIG

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'